The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme consists of three randomised, double-masked, parallel, placebo-controlled studies to determine the impact of treatment with candesartan on diabetic retinopathy. In Type 1 diabetes, 1,700 patients without retinopathy will be randomised into a primary prevention study, and 1,200 with nonproliferative retinopathy into a secondary prevention study. In Type 2 diabetes, 1,600 patients with nonproliferative retinopathy will be randomised. Patients will be followed for at least three years. Eligible patients must be normotensive (systolic blood pressure [SBP] < 130 mmHg and diastolic blood pressure [DBP] < 85 mmHg) without antihypertensive medication in Type 1 diabetes, and either normotensive or treated hypertensive (SBP < 160 mmHg and SBP < 90 mmHg) and not taking angiotensin-converting enzyme inhibitors or AT 1receptor blockers in Type 2 diabetes. All patients will be normoalbuminuric, based on two overnight urine collections. The primary endpoint is based upon retinal photographs, graded to the Early Treatment of Diabetic Retinopathy Study scale. A two-step increase on this scale defines incidence, and a three-step increase defines progression of retinopathy. The main secondary endpoint for each study is change in urinary albumin excretion rate. A positive outcome of the DIRECT Programme would be an important step forward in the clinical management of patients with diabetes.
Introduction
Retinopathy is one of the most frequent complications of diabetes, eventually occurring in nearly all patients [1] [2] [3] and is the commonest cause of blindness in people of working age. 4 In Type 2 diabetes, it is estimated that around 20% of patients have retinopathy at diagnosis. 5, 6 Laser photocoagulation of retinopathy greatly reduces the risk of blindness, 7 and is used when retinopathy is relatively advanced, and when damage to the vasculature has already occurred. Further, photocoagulation may result in constriction of the visual fields, night blindness, and worsening of macular oedema. 7 Strict glycaemic control significantly reduces the incidence and progression of retinopathy in diabetes, 8 but it cannot wholly prevent disease progression. 9 Further, tight glycaemic control is often difficult to achieve in routine clinical practice and in Type 1 patients particularly, the risk of severe hypoglycaemic events needs to be balanced against the potential benefits. 10 There is therefore a need to explore alternative interventions in order to reduce the burden of the microvascular complications of diabetes. Systemic blood pressure (BP) is one such modifiable risk factor. BP is positively correlated with the prevalence of retinopathy, 9 and is also a powerful determinant of incidence. 11 The EURODIAB Controlled trial of Lisinopril in Insulin-dependent Diabetes (EUCLID) and UK Prospective Diabetes Study (UKPDS) studies are the largest and most robust to date, exploring the impact of treatment with antihypertensive drugs on retinopathy in Type 1 and Type 2 diabetes, respectively. 12, 13 EUCLID showed a 50% reduction in the progression of retinopathy on a 5-level scale over a two-year period in normotensive people with Type 1 diabetes treated with lisinopril. Progression to proliferative retinopathy was also significantly reduced. Importantly, there were indications that both incidence and regression of retinopathy were favourably influenced by lisinopril, though neither effect was statistically significant. 12 Similarly, atenolol and captopril in the UKPDS demonstrated a reduction in the need for retinal photocoagulation in hypertensive people with Type 2 diabetes. 13 The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme has been designed to answer some of the questions which remain from EUCLID and the UKPDS. The original idea and study design was conceived by key members of the EUCLID Study Group, and further developed into the current protocol by the Steering Committee.
Materials and methods

Programme objectives
The DIRECT Programme is designed to determine the effects of blocking the angiotensin II Type 1-(AT 1 ) receptor on retinopathy in normoalbuminuric patients with Type 1 and Type 2 diabetes.The Type 1 patients are exclusively normotensive at randomisation, whilst Type 2 patients include both treated hypertensive and normotensive patients. The primary objectives include: G To examine the effect of treatment on the incidence of retinopathy in Type 1 diabetic patients. G To examine the effect of treatment on progression of retinopathy in Type 1 and Type 2 diabetic patients. The secondary objective is to examine the effect of treatment on albumin excretion rate (AER) in each population studied, and the incidence of microalbuminuria in all three populations combined.
Programme design
Three double-masked, placebo-controlled, parallel design, randomised clinical trials comprise the Programme. In Type 1 diabetes, there is a primary and a secondary prevention study, which will examine the effect of treatment on incidence and progression of retinopathy, respectively. Secondary prevention will be studied in Type 2 diabetes. Four thousand, five hundred patients will be randomised at approximately 300 centres worldwide.
Interventions
Participants are randomised to either active treatment (AT 1 -receptor blocker [ARB] candesartan cilexetil, 16 mg), or matching placebo. After one month, the drug dose is doubled to 32 mg of candesartan or placebo, according to tolerability.
Duration of treatment period
Patients will be followed for at least three years.
Inclusion and exclusion criteria
Most inclusion and exclusion criteria are common to all three studies in the Programme ( Table 1 ). All patients are normoalbuminuric, i.e. an average albumin excretion rate of < 20 µg/minute in two overnight urine collections measured at a central laboratory. An upper limit of duration of diabetes has been chosen in order to ensure that the majority of people are still at risk of development or progression of retinopathy, and is derived from the Wisconsin Epidemiological Study of Diabetic Retinopathy cohort (WESDR) 11 and EURODIAB studies (unpublished data). Type 1 patients are all normotensive (systolic BP [SBP] < 130 mmHg and diastolic BP [DBP] < 85 mmHg) and not on antihypertensive medication. However, Type 2 diabetic patients may be normotensive or have treated hypertension. Restricting entry to Type 2 diabetic patients who satisfy the strict JNC VI guidelines (BP < 130/85 mmHg) 14 would severely limit eligibility and make the results difficult to generalise.A lower limit of BP has not been chosen, as BP reduction is not assumed to be necessary to achieve the desired effect. 15, 16 
Enrolment visit
Written informed consent is obtained before any procedures are performed. BP is measured three times in a sitting position, using an automated device (OmronM4).The mean of the last two measures is used to assign BP status. A spot urine is tested for infection, and then for crude assessment of microalbuminuria, using the Micral test. If both of these are negative, the patient is provided with two collection pots for overnight urine collections. Bloods are taken for baseline lipids (cholesterol and HDL), and glycated haemoglobin. Samples are sent to a central laboratory for these analyses. In addition, safety laboratory tests, including serum creatinine and potassium, are performed locally.A detailed ophthalmological examination, including measurement of visual acuity, to a standard protocol, is performed in order to rule out ophthalmic exclusion criteria. 17 Seven field stereo retinal photographs are taken and graded to the Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol. 18, 19 Staff at participating centres are trained and certified in taking these photographs. Films are sent to a central processing laboratory, mounted centrally at the Academic Co-ordinating Centre, and then graded at the Retinopathy Grading Centre, both at Imperial College. Graders are masked to all patient information, including true patient numbers. All photographs are independently graded by two separate graders.
Randomisation visit
When the results of the retinal grading and the centrally measured AER are available, randomisation is performed.A general physical examination, including BP measurement and measures of central obesity, is performed. Patients are started 256 PAPER on candesartan, 16 mg once-daily, or a matching placebo. Randomisation is performed centrally by a computerised system.
Frequency and duration of follow-up
The overall design of the DIRECT Programme is shown in Figure 1 . The key outcome measures, retinopathy and AER, are measured annually, based on seven field stereo fundus photographs and two overnight urine collections respectively.
Final visit
Each study will continue until every patient has completed three years of follow-up.The final study examination will include retinal photographs,visual acuity and urine collections for measurement of AER.
Progression to hypertension or microalbuminuria
Patients who become hypertensive and those who become microalbuminuric ( Figure 2 ) will attend an interim visit. If hypertension or microalbuminuria persists, patients will be treated. Patients will be treated with an angiotensin-converting enzyme (ACE) inhibitor for microalbuminuria, regardless of hypertension status.Type 2 patients with hypertension and no evidence of microalbuminuria, will be treated with an antihypertensive medication other than ACE inhibitor (ACE-I) or ARB. In the event that optimal BP is difficult to achieve,ACE-I treatment is permitted.
Progression to study endpoints
Patients reaching the primary endpoint for their study will still continue in the Programme on medication, as there remains scope to reach a secondary endpoint. If the local investigator decides that the patient requires laser therapy, a full set of photographs will be required before treatment and the reason for laser therapy will be documented.
Outcome measures Study specific analyses
The primary outcome measure is a change in retinopathy level, either incidence or progression. 
x (x) only secondary prevention studies UAER = Urinary albumin excretion rate BP = blood pressure maximise therapy if necessary add in non ACE-I Incidence is defined as a two-step progression from 10/10 on the ETDRS scale. 18 Progression is defined as a three-step change. Primary outcomes will be assessed separately in each study, i.e. primary prevention in Type 1, secondary prevention in Type 1 and secondary prevention in Type 2 diabetes. The secondary efficacy variable for each study is rate of change of AER. For the secondary prevention studies only, an additional secondary efficacy variable is the incidence of clinically significant macular oedema (CSME), and/or proliferative diabetic retinopathy (PDR), according to the ETDRS protocol. 18 Other efficacy variables for each study include serum total and HDL cholesterol, and glycaemic control.
Pooled analyses
Analyses will be performed across all three study populations for the following outcomes: G The primary objective is the incidence of microalbuminuria, defined as the occurrence of at least three out of four samples with UAER ≥ 20 µg/minute at any visit after randomisation. G The secondary objectives include progression to CSME and PDR separately, and combined. G Regression of retinopathy, defined as a reduction in retinopathy level by at least three steps from baseline. Rate of change of urinary AER. Other objectives include: glycaemic control, cholesterol, and threeline loss of visual acuity in at least one eye, will also be assessed.
Sample size
All sample sizes are calculated to perform hypothesis tests with a two-sided significance level of 5% and at least 90% power. For assumptions on event rates, published and unpublished data from the WESDR 11 and EUCLID 12 studies were used in the calculation of sample sizes in Type 1 diabetes, while assumptions on treatment effects were based on evidence from the EUCLID trial. Estimates for the trial in Type 2 diabetes used WESDR data 11 for assumptions concerning event rates in the placebo group, and UKPDS and the study by Ravid et al. for the treatment effect. 13, 20, 21 These assumptions, as well as assumptions on withdrawal rates of 15% for all three trials and rates of patients on placebo receiving some form of active treatment (crossovers) were used in Monte Carlo simulations. Random distribution models were used to generate event rates and assessment times, and other assumptions for the trial. Power corresponding to different configurations of sample size and event rates was determined empirically from the number of test statistics above the 5% significance limit in the replication samples. The Programme is powered to detect a mean reduction in risk ratio of 23% in the primary prevention study, 24% in the secondary prevention study in Type 1 diabetes, and a 27% reduction in the secondary prevention study in Type 2 diabetes.
For the pooled analyses, although no formal sample size calculations have been performed, analysis of data from previous studies show that the cumulative rate of progression of microalbuminuria to be expected in these patient populations is 11%. The numbers available for pooled analyses will thus yield a power of at least 80% to detect a reduction in relative risk of 23% for a twosided test at 5% significance level.
Proposed analysis
Assessment of the main endpoint will be performed on an intention-to-treat basis to compare the relative risk of incidence or progression of active treatment with respect to placebo.The exact time of the occurrence of an event will not be known, the only time available being the time when the retinal photographs were taken. Thus, event rates will be assessed applying methods for interval censored data, and the Mantel-Haenszel statistic, a discrete version of the log-rank test, will be used to compare treatments. Additional analyses, providing a description of treatment effects on cumulative event rates and entailing adjustments accounting for observed patient characteristics will be provided.
Programme management and committees
The Steering Committee has defined the scientific nature of the study and will be responsible for all primary publications. An International Co-ordinators Group meets regularly with the Steering Committee, to discuss and inform on scientific and logistical issues. The operational aspect of the study is managed by the DIRECT Project Team, which includes representatives from the Sponsors, the Contract Research Organisation, the Retinopathy Grading Centre, the Academic Coordinating Centre and the central laboratory. An Executive Committee (marked with an asterisk in the Steering Committee and DIRECT Project Team listings), is responsible for overseeing daily activities during the study. An Independent Safety Committee will review all safety data during the course of the study.
The Programme protocols have been approved by Ethics Committees and regulatory bodies in all centres and countries participating in the DIRECT Programme.
Discussion
The potential impact of RAS blockade on diabetic retinopathy
Considerable interest in the use of ACE inhibition in patients with retinopathy was generated after the beneficial effects observed in EUCLID in Type 1 diabetes, and subsequently in the UKPDS in Type 2 diabetes. 12, 13 Strict glycaemic control reduces both the onset and progression of retinopathy by at least 50% after nine years in people with Type 1 diabetes 22 and, in Type 2 diabetes, the risk of retinal photocoagulation by approximately 30%. 9 In contrast, treatment with lisinopril in normotensive type 1 patients in EUCLID reduced the risk of retinopathy progression by 50% over just two years, 12 indicating that renin-angiotensin system (RAS) blockade may be more effective, at least in the eye, than glycaemic control in the management of microvascular complications. 
Choice of study medication
The benefits of the additional non-haemodynamic effects of inhibition of the RAS are reflected in the emphasis on the use of these agents for microvascular disease in diabetes. 23 ACE-Is and ARBs are superior to other classes of drug, such as calcium channel blockers or β-blockers, in terms of slowing progression of renal disease, [24] [25] [26] [27] at least in those with established albuminuria, although there are no sufficiently powered studies looking at the impact of RAS blockade on the development of microalbuminuria in Type 1 and Type 2 diabetes. Given that the mechanisms of the beneficial effect of ACE-Is on nephropathy and retinopathy are thought to be similar, it is unlikely that other classes of agent would be substantially better in terms of retinopathy.
ACE-Is act mainly by inhibiting angiotensin II (Ang II) synthesis, and have been highly successful in the treatment of hypertension generally, owing to their tolerability and good safety record. However, the side-effect of cough is common, and compliance is consequently reduced. 28 Furthermore, there are other metabolic pathways to Ang II production which are not blocked by ACE-Is. A more specific blocker of Ang II may overcome these limitations, and there is now evidence comparing ACE-Is with ARBs. These studies show that this newer class of drug is better tolerated, and has fewer side-effects, including hypotension. There are some reports which suggest that ACE-Is improve insulin sensitivity, an effect apparently not shared by ARBs, 29,30 and may therefore be more acceptable to patients prone to hypoglycaemia. Thus, for superior tolerability and more effective RAS blockade, an ARB is an attractive alternative. 31 Candesartan is a highly selective ARB with no agonist activity. It binds tightly to, and dissociates slowly from the AT 1 -receptor. 32 To enhance bioavailability, a prodrug, candesartan cilexetil, is administered, which is rapidly and completely converted to the active compound during absorption from the gastrointestinal tract. Candesartan cilexetil is currently indicated for the treatment of hypertension, and is characterised by good tolerability, a smooth onset of action and a long-lasting BP-lowering effect. 15, 33 For the antihypertensive effect, there is a doseresponse relationship, but whether the relationship is similar for organ protection is not fully known. In many European countries, the presently approved top dose of candesartan cilexetil in hypertension is 16 mg o.d. However, even if some haemodynamic effects, such as renal plasma flow, demonstrate a flat dose-response relationship from 16 mg to 32 mg, the higher dose blocks the RAS more effectively, as reflected by higher levels of circulating renin. 16 Furthermore, a BP-independent dose-dependent renoprotective effect of AT 1receptor blockade has recently been reported, 26 indicating beneficial effects of a high dose. When selecting the dose for a clinical trial, it is essential to have the desired effect and at the same time preserved tolerability. Candesartan cilexetil has no dose-related adverse events, and the 32 mg dose, which achieves effective AT 1 -receptor blockade over 24 hours, can be used in a clinical trial, including normotensive individuals. The experience in normotensive individuals indicates that BP is not significantly affected and tolerability is good. 15, 16 In the present Programme, a relatively high dose of candesartan is used. Another reason for the choice of dose is experimental evidence in some models that the organ protective effect may require a higher dose. 34
Choice of endpoint
Incidence of diabetic retinopathy is defined as a change from baseline to any set of retinal photograph taken after randomisation by at least two steps from 10/10 in the ETDRS severity scale.Two steps are defined as either a 1-step change in each eye or as a 2-step change in one eye only.
In the present study, definition of development of diabetic retinopathy, as measured by the ETDRS severity scale, makes use of a 2-step change in this scale. The use of a 2-step change from a level of 10/10 as a measure of incidence is justified, since this outcome has equivalent predictive power as a 3-step change with respect to the risk of developing proliferative diabetic retinopathy.The rationale for the choice of this endpoint is based on reanalyses of the epidemiological data from the WESDR. In this population-based study, progression of retinopathy was studied in patients with Type 1 diabetes and no retinopathy at the study start. Both a 2-step or more and a 3-step or more progression on the ETDRS severity scale over the first four years was associated with an increased odds ratio for developing proliferative diabetic retinopathy over the next ten years. For a 2-step or more progression, the risk ratio of developing proliferative diabetic retinopathy was 5.1 (95% CI 3.7-7.1), compared with 4.6 (95% CI 3.5-6.1) for a 3-step or more progression.Thus, the predictive power of a 2-step or more change in retinopathy is similar to a 3-step or more change and both significantly predict the 10-year progression to proliferative diabetic retinopathy and clinically significant macular oedema. 35 
Importance of the DIRECT Programme
Diabetes prevalence is increasing worldwide, and is predicted to double within the next 20 years. 36 The risk of retinopathy, one of the commonest complications of diabetes, can to some degree be reduced by tight glycaemic control, which is currently the only proven therapy in this area. A positive outcome of the DIRECT Programme will represent a major advance in diabetes management, as it will, for the first time, determine whether candesartan can prevent the onset or progression of diabetic retinopathy. The Programme will also generate unique information on the ability to prevent the occurrence of microalbuminuria. 
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